Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”

Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the poster here or use the link below to download a copy for a closer look:

7 Reasons to Join ViraxImmune™’s T Cell Test Early Access Program

This week, we were excited to launch ViraxImmune™’s Research Use Only (RUO) Early Access Program. This program is designed to provide a new research tool and community for those committed to advancing the field of immune assessment, starting with our RUO application T-cell test for SARS-Cov-2. Here are some reasons that we think you should join this program and sign up for our introductory webinar on LinkedIn Live: ** Participation in ViraxImmune™’s Early Access Program is an opportunity to engage with our novel peptide mix for use in adaptive immunity assessment: we are working hard to facilitate an opportunity to be part of a broader research effort in immune system understanding. Together, we can explore the intricacies of immune responses, forge innovative solutions, and collectively elevate the field of immunology. If you are driven to expand the horizons of immune assessment research, we encourage you to register for our introductory webinar on LinkedIn Live. ViraxImmune™ stands ready to support your research endeavors as we collectively shape the future of immunology: we’re keen for you to join along. Caution Concerning Forward Looking Statements: This blog post contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives might not occur. Media and Investor Contact: